[go: up one dir, main page]

WO2009074239A1 - Mousses pharmaceutiques - Google Patents

Mousses pharmaceutiques Download PDF

Info

Publication number
WO2009074239A1
WO2009074239A1 PCT/EP2008/010151 EP2008010151W WO2009074239A1 WO 2009074239 A1 WO2009074239 A1 WO 2009074239A1 EP 2008010151 W EP2008010151 W EP 2008010151W WO 2009074239 A1 WO2009074239 A1 WO 2009074239A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically active
glycerides
composition
propellant
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/010151
Other languages
English (en)
Inventor
Giancarlo Ceschel
Gabriele Vecchi
Flavia Giuliana Tinti
Carlo Oliani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MONTERESEARCH-PHARMACEUTICAL DEVELOPMENT SERVICE
Original Assignee
MONTERESEARCH-PHARMACEUTICAL DEVELOPMENT SERVICE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MONTERESEARCH-PHARMACEUTICAL DEVELOPMENT SERVICE filed Critical MONTERESEARCH-PHARMACEUTICAL DEVELOPMENT SERVICE
Priority to EP08860575A priority Critical patent/EP2231119A1/fr
Publication of WO2009074239A1 publication Critical patent/WO2009074239A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Definitions

  • the present invention relates to pharmaceutical compositions that are applied as a foam.
  • compositions for topical application which have improved absorbency by the skin particularly human skin.
  • the invention provides improved surfactant formulations useful in pharmaceutical compositions that are applied as foams.
  • This invention therefore provides the use of combination of non-hydrogenated lecithin and other surfactants as ingredients for foams having pharmaceutical uses.
  • non-hydrogenated lecithin and polyglycolyzed glycerides has been found particularly advantageous to enhance the absorption of active ingredients into the skin from pharmaceutical formulations applied as a foam.
  • the invention further provides pharmaceutical formulations applicable as a foam containing a combination of non- hydrogenated lecithin and other surfactants.
  • Topical applications of pharmaceutical active ingredients are widely used and have the benefits, when compared to oral or i.v. administration, that gastric/renal side effects can be limited and higher doses can be applied.
  • Active pharmaceutical ingredients of several classes are formulated and applied as ointments, creams, gels, lotions, topical solutions.
  • Lotion and gel topical dosage forms have the disadvantage that extended rub-in may be required and may leave oily residues.
  • the solution form has the disadvantage that it readily runs off the site of application, and therefore it is difficult to apply controlled amounts of the solution.
  • Foams and aerosols are dosage forms applied from a pressurised canister and containing one or more active pharmaceutical ingredients that, upon valve actuation, are released from the container as a fine dispersion of liquid and/or solid materials in a gaseous medium such as from an aerosol.
  • foams as means of topical administration of pharmaceutical active ingredients is described in US Patent Application publication number 2007/77208, European Patent Application EP502502A, and the American Journal of Drug delivery 2003, 1, 73; Expert Opinion on Drug Delivery, 3, 799 and references cited therein). Due to physico-chemical processes taking place once the foam is applied on the skin, drug delivery rate is generally higher than that obtainable by application of solutions or emulsions of the active ingredient.
  • formulations for application as a foam typically contain a liquid carrier, a propellant, an emulsifier for dispersion of the active ingredient in the liquid carrier.
  • Other additives may be included in the formulation for several reasons depending on the nature of the active ingredient; for example additives may be included to enhance percutaneous penetration, to improve foam formation and stability (emulsifiers) and to assure microbiological purity over time.
  • the formulation is such that it can be pressurised within a container and expelled from the container as a spray when a valve is activated to allow release of the foam from the container.
  • Formulation ingredients can have a significant effect on percutaneous absorption of the pharmaceutical active ingredient and on overall efficacy of the drug action. It has now been found that the use of non-hydrogenated lecithin's and their derivatives in combination with other surfactants have unexpected synergistic effects in improving the active ingredient delivery rate of pharmaceutical formulations topically applied as foam.
  • Lecithins and their derivatives may be synthetic or naturally occurring and lecithins of natural origin are mixtures composed mainly of phosphatidylcholine and other phospholipids Lecithins are known to moisturise skin and mucosal tissues and facilitate penetration of active ingredients into the skin
  • Lecithin and partially hydrogenated lecithin are used as excipient for topical pharmaceutical formulations comprising, among others, moisturising creams (United States patent 6316428), emulsions for nasal administration (United States Patent 5179079) and creams to treat psoriasis (United States Patent Application 2002012648, United States Patent 5945409). They have also been proposed for use in foams containing anti-inflammatory agents
  • Glycerides such as caprylocaproyl macrogolglycerides (commercially available as Labrasol) are used as emulsifiers and as absorption enhancers in pharmaceutical and cosmetic formulations, both for topical and oral administration (e.g. Clinical pharmacology and therapeutics 2000, 68, 114).
  • compositions in the form of foams comprising a combination of non-hydrogenated lecithin and/or its derivatives and glycerides, particularly caprylocaproyl macrogolglycerides, allow enhanced topical absorption of pharmaceutically active ingredients.
  • the present invention provides the use of a mixture of non-hydrogenated lecithin and one or more glycerides as a surfactant in a foamable composition comprising a pharmaceutical active ingredient for topical application.
  • the invention provides a composition
  • a composition comprising i) a pharmaceutically active ingredient for topical application ii) a liquid carrier iii) a propellant iv) a surfactant comprising a mixture of non-hydrogenated lecithin and one or more glycerides or their derivatives.
  • the invention provides a pressurised container equipped with a contents release valve containing a composition comprising i) a pharmaceutically active ingredient for topical application ii) a liquid carrier iii) a propellant iv) a surfactant comprising a mixture of non-hydrogenated lecithin and one or more glycerides or their derivatives.
  • the invention provides the topical treatment by application to skin of a foam comprising i) a pharmaceutically active ingredient for topical application ii) a liquid carrier iii) a propellant iv) a surfactant comprising a mixture of non-hydrogenated lecithin and one or more glycerides or their derivatives.
  • the preferred glycerides are caprylcaproyl macrogol glycerides.
  • one or more antioxidants may be included in the formulation to improve the stability of the formulation over time.
  • active ingredient 'active agent', 'at least one pharmaceutically active compound' and 'pharmaceutically active agent' are used interchangeably herein and refer to a substance having a pharmaceutical, pharmacological or therapeutic effect.
  • Pharmaceutically acceptable salt of an active compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • Carrier' refers to a composition which has only excipient properties or components required to carry an active agent, but which itself has no pharmaceutical or therapeutic effect.
  • the at least one pharmaceutically active compound comprises a combination of active agents.
  • Any combination of active agents suitable for topical administration can be used in the compositions of the present invention.
  • the combination of active agents comprises at least two agents selected from an antibacterial agent and an antifungal agent.
  • a topical delivery composition in a pressurised container comprises up to 15 % wt of at least one pharmaceutically active compound, or its pharmaceutically acceptable salt; from about 83 % to about 97.9 % wt of a carrier; and from about 2 % to about 7 % wt of an aerosol propellant selected from the group consisting of a hydrocarbon or a hydroflurocarbon, a chloroflurocarbon, and a mixture thereof.
  • compositions of the present invention are present in a pressurized container comprising a homogenous mixture of from about 0.1 % to about 10 % wt of a pharmaceutically active ingredient, or its pharmaceutically acceptable salt from about 83 % to about 97.9 % wt of a carrier, and from about 2 % to about 79 % wt of an aerosol propellant selected from the group consisting of a hydrocarbon, a hydrofluorocarbon and a mixture thereof and a surfactant system comprising non-hydrogenated lecithin and a glyceride.
  • the maximum amount of propellant used is often determined by its miscibility with other components in the composition to form a mixture, such as a homogeneous mixture.
  • the minimal level of propellant used in the composition is often determined by the desired foam characteristics and its ability to substantially or completely evacuate the container.
  • Water and optionally a pH-adjusting agent generally comprise the remaining portion as a carrier.
  • the amount of water present ranges from about 10 % to about 95 % wt, preferably from about 10 % to about 90 % wt more preferably from about 20 % to about 90 % wt with from about 30 % to about 40 % wt or alternatively from about 80 % to about 95 % wt.
  • the pressurized container is a one-piece aluminium container in which the inner surface is lined with a chemically inert lining.
  • a preferred inner surface lining is polyamide-imide (PAM) lacquer.
  • PAM polyamide-imide
  • the container is fitted with an upright or inverted valve and a conventional foam spout actuator.
  • the invention is applicable for the topical administration of any pharmaceutically active material. It has been found that the invention is particularly useful with at least one pharmaceutically active material chosen from anti-inflammatory, myorelaxing, antimicotic, antihistaminics, antibiotics, local anesthesics and analgesic active pharmaceutical ingredients and combinations thereof.
  • the invention is also useful for the topical delivery of steroidal and non-steroidal anti-inflammatory pharmaceutical agents as well as non steroidal inflammatory active materials such as diclofenac, nimesulide, ketoprofene.
  • the active ingredient is hydrocortisone acetate.
  • the active ingredient is sodium butyrate.
  • the active ingredient is econazole.
  • Non-hydrogenated lecithin as used herein includes synthetic lecithins and their derivatives and also includes naturally occurring lecithin and the non-hydrogenated versions of lecithin of natural and synthetic lecithin and their derivatives.
  • Lecithin refers to a material which is a phosphatide on naturally occurring or synthetic phosphatides can be used.
  • Phosphatidylcholine is the preferred form of lecithin and is a derivative of glycerine esterified with a choline ester of phosphoric acid and two fatty acid groups which may be the same or different.
  • the fatty acids are saturated or unsaturated fatty acids, having 16-20 carbons and containing up to 4 double bonds.
  • Natural lecithins can be extracted from vegetable matter (e.g. sunflower seeds, soybeans, safflower seeds and cottonseed), animal (e.g. egg yolk) or lecithins of synthetic origin can be used.
  • the preferred structure of the lecithin will depend upon the nature of the pharmaceutical active ingredient.
  • a definition of lecithin may be found in Stedman's medical dictionary 21 $t ed., page 8791 which defines lecithin as any of a group of phospholipids which upon hydrolysis yield two fatty acid molecules and a molecule each of glycerophosphoric acid and choline. There are therefore several varieties of lecithin.
  • Lecithin is a mixture of the diglycerides of stearic, palmitic, and oleic acids, and palmitoleic, linoeic, linolenic, and arachidonic acids, linked to the choline ester of phosphoric acid.
  • Soybean lecithin is a preferred lecithin and may contain the following acids; palmitic, stearic, palmitoleic, oleic, linoleic, linolenic and arachidonic. In some lecithins both fatty acids are saturated while others contain only unsaturated fatty acids for example, oleic, linoleic or arachidonic.
  • lecithins In other lecithins one fatty acid is saturated, the other unsaturated.
  • Lecithins are found in nervous tissue, hepatic tissue, cardiac tissue, in egg yolks and in soy which constitutes the most common and economical source of phosphatidylcholine. Accordingly any reference herein to non-hydrogenated lecithin or phosphatidylcholine is intended to include any combination of non-hydrogenated lecithin-like phospholipids compounds.
  • examples of other phospholipids which can be used in accordance with the present invention include phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid.
  • a mixture of any of the above phospholipids may also be used in the present invention. Mixtures of these phospholipids are present in a natural soy lecithins.
  • glyceride refers to an ester of glycerol with carboxylic acids and includes mono-, di - and tri-glycerides and mixtures thereof. Glyceride includes synthetic and naturally occurring glycerides and derivatives thereof.
  • polyglycolised glyceride refers to esters of glycerol that have been ethoxylated or propoxylated. These materials can be complex mixtures of compounds derived from the reaction of glycerol and/or its derivatives, ethylene and/or propylene oxide and carboxylic acids which may themselves be mixtures of carboxylic acids.
  • polyglycolyzed glyceride refers to specific mixtures of mono-, di- and triglycerides and polyethylene glycol mono and diesters, obtained either by partial alcoholysis of hydrogenated vegetable oils using polyethylene glycol.
  • the "polyglycolyzed glycerides” may be saturated or unsaturated and may be complexes of ethoxylated glycerides and polyethylene glycol esters.
  • the saturated polyglycolyzed glyceride is a glyceryl caprylate/caprate and PEG-8 (polyethylene glycol) caprylate/caprate complex commercially available as Labrosol is a preferred material.
  • the polyglycolyzed glycerides of the present invention have Hydrophilic Lipophilic Balance (HLB) values of between and including 6 and 14 typically the free glycerol content is less than 3%.
  • HLB Hydrophilic Lipophilic Balance
  • suitable polyglycolyzed glycerides include Labrafac.RTM.CM 10, Labrafil.RTM.M 10, Labrafil.RTM. NA10, Labrafac.RTM.CM 12, Labrasol.RTM. (Labrafac.RTM.CM 14) and the like.
  • polyglycolyzed glycerides examples include Labrafac.RTM.CM 6, Labrafil.RTM. WL2609 BS, Labrafac.RTM.CM 8, Labrafac.RTM.CM10, Labrafil.RTM.M 10, Labrafil.RTM. NA10, Labrafac.RTM. CM12, and Labrasol.RTM. (Labrafac.RTM. CM 14).
  • Preferred polyglycolyzed glycerides having HLB values of between 6 and 14 inclusive, and containing medium chain (C 8 - C 10 ) triglycerides, are Labrafac.RTM.
  • Analogs and derivatives of the above polyglycolyzed glycerides are also suitable for use in the compositions and methods of the present invention. To the extent that these analogs and derivatives are similar in structure to or are readily obtained by chemical modification of the polyglycolyzed glycerides. While substantially retaining the physical properties of the polyglycolyzed glycerides, such analogs and derivatives are intended to be included among the compositions and methods of the present invention.
  • the term “foam” refers to finely dispersed suspensions of liquid and/or solid materials in a gaseous medium, the suspension being released from pressurized containers as droplet dosage foams upon actuation of the valve of the container.
  • the present invention therefore provides various pharmaceutically active topical compositions applied as foams based on the finding that the combined use of non-hydrogenated lecithin and glycerides, particularly polyglycolyzed glycerides produce a synergistic effect resulting in an enhanced absorption of the active pharmaceutical ingredient by the skin and an easier delivery of the drug.
  • the topical compositions of the present inventions are solutions or suspensions suitable to be delivered as a foam or droplets from a pressurised container upon actuation of a valve.
  • the foam preferably contains the active pharmaceutical ingredient in a concentration between 0.5 and 10% weight/volume together with non-hydrogenated lecithin in concentration between 0.1 % and 10%, and glycerides in concentration between 5% and 30%.
  • the non-hydrogenated lecithin is present in a concentration between 0.1 % and 5 % and the glyceride is in a concentration between 8% and 15%.
  • the non-hydrogenated lecithin is present in a concentration between 0.3% and 0.5% and the glyceride is present in a concentration between 9 % and 11 % the balance of the formulation being other additives and a carrier such as water.
  • the foam compositions can be applied for absorption on the skin of humans or animals or, varying the ingredient ratios as suitable, vaginal, rectal, buccal mucose.
  • the invention is particularly useful with formulations in which the active pharmaceutical ingredient is one or more of anti-inflammatory, myorelaxing, antifungal, antihistamines, antibiotic, local aesthetic and analgesic agents.
  • the invention in particular is useful in the provision of a topically applied composition for delivery of steroidal and non-steroidal anti-inflammatory pharmaceutical agents, in particular the active pharmaceutical ingredients can comprise, but are not limited to, diclofenac, hydrocortisone acetate, nimesulide, ketoprofene, tiocolchicoside and sodium butyrate.
  • compositions may contain additional components such as perfumes, bacteriostatic agents (e.g. benzyl alcohol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate and analogues), anti-oxidants (e.g. tocoferol acetate, butyl hydroxy anisole, butyl hydroxyl toluene and analogues).
  • bacteriostatic agents e.g. benzyl alcohol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate and analogues
  • anti-oxidants e.g. tocoferol acetate, butyl hydroxy anisole, butyl hydroxyl toluene and analogues.
  • Non-hydrogenated lecithin and/or its derivatives is used.
  • Non-hydrogenated lecithins do not require elaborated purification treatments, and provide a cost-effective solution for the production of pharmaceutical foams which is particularly suitable for industrial production.
  • transdermal permeability of the active pharmaceutically ingredient used in the formulations was evaluated using Franz cells permeation test using porcine inner ear epidermis as the septum between the formulation (donor compartment) and the receptor phase chamber.
  • porcine epidermis is the preferred model as it displays permeation properties similar to those of human skin (International Journal of Pharmaceutics 2007, 331 , 139).
  • the compartment had 4.8 ml_ capacity.
  • the receptor chamber is encircled in a jacket in which water is circulated at 37 ⁇ 1 0 C.
  • the samples of skin are taken from the inner ear of the pig as soon as sacrificed and dipped, for 24 h, in a solution buffer at pH. 7.4 held at 4 0 C.
  • the connectival parts are removed by surgical technique and the remaining skin is cut in squares of 2x2 cm. The squares obtained are conserved until use at 20 0 C.
  • the test is conducted by positioning the porcine skin between the donor compartment and the receptor chamber with the external surface towards the upper compartment.
  • the foam pharmaceutical formulation is placed inside the donor compartment.
  • the receptor chamber is then filled up with phosphate buffer at pH 7.4. 2 ml of the buffer solution are then sampled at regular time intervals and analysed for the content of the active pharmaceutical ingredient, when a sample is removed the initial volume of the solution is restored with phosphate buffer heated at 37°C. The samples thus obtained are stored at to 4°C until the quantitative analysis is performed.
  • the test is repeated 9 times for every formulation and the samples obtained are analysed by HPLC.
  • the chromatographic conditions used for the determination of the active ingredient were as follows.
  • diclofenac sodium salt is dispersed in purified water under stirring, until complete dissolution is obtained.
  • Non-hydrogenated phosphatidilcoline (lecithin) is dissolved in purified water and then introduced into the main container together with the flavouring agent and stirred for 15-20 minutes.
  • the formulation is then diluted to the required volume with purified water and stirred for 15-20 minutes with pH control (limits: 7-9).
  • the solution is then filtered under pressure.
  • the desired weight of the solution is placed into a canister provided with a valve and then a propellant gas is pumped into the canister, to pressurise the formulation and provide 5 wt % propellant.
  • the propellant gas was a mixture of 80 % isobutane and 20 % n-butane.
  • the formulation was produced in a manner similar to that described in Example 1 , with variations of some excipients and of the active ingredient.
  • Example 3- hydrocortisone Foam The formulation was produced in a manner similar to that described in Example 1 , with variations of some excipients and of the active ingredient; composition of the solution, expressed percentage was
  • caprylocaproyl macrogol glycehdes (Labrasol) 5.000 7 non-hydrogenated phosphatidylcholine (lecithin) 0.300
  • Example 4- thiocolchicoside Foam The formulation was produced in a manner similar to that in Example 1 , except that the lecithin was not employed, the formulation had the following composition in percentage terms
  • the formulation was produced in a similar manner to that described in Example 1.
  • the final composition of the solution, expressed in %. was 1 Econazole 3.000

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur des mousses pour l'application topique d'ingrédients pharmaceutiquement actifs, qui sont à base d'une combinaison tensioactive de lécithine non hydrogénée et de glycérides ou leurs dérivés. L'invention porte également sur l'utilisation de la combinaison tensioactive qui conduit à une absorption améliorée de l'ingrédient actif par la peau.
PCT/EP2008/010151 2007-12-12 2008-11-30 Mousses pharmaceutiques Ceased WO2009074239A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08860575A EP2231119A1 (fr) 2007-12-12 2008-11-30 Mousses pharmaceutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0724236.5 2007-12-12
GB0724236A GB0724236D0 (en) 2007-12-12 2007-12-12 Pharmaceutical foams

Publications (1)

Publication Number Publication Date
WO2009074239A1 true WO2009074239A1 (fr) 2009-06-18

Family

ID=39016470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/010151 Ceased WO2009074239A1 (fr) 2007-12-12 2008-11-30 Mousses pharmaceutiques

Country Status (3)

Country Link
EP (1) EP2231119A1 (fr)
GB (1) GB0724236D0 (fr)
WO (1) WO2009074239A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012057894A1 (fr) 2010-10-26 2012-05-03 Quinnova Pharmaceuticals, Inc. Composition d'econazole et méthodes de traitement au moyen de cette composition
US20140073616A1 (en) * 2012-09-11 2014-03-13 Gary Marder Hydrocortisone nanotechnological delivery system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085127A1 (fr) * 2005-02-08 2006-08-17 Antibe Therapeutics, Inc. Compositions topiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085127A1 (fr) * 2005-02-08 2006-08-17 Antibe Therapeutics, Inc. Compositions topiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FIUME Z: "Final report on the safety assessment of Lecithin and Hydrogenated Lecithin", INTERNATIONAL JOURNAL OF TOXICOLOGY, TAYLOR AND FRANCIS, WASHINGTON, DC, US, vol. 20, no. SUPPL 1, 1 January 2001 (2001-01-01), pages 21 - 45, XP008102244, ISSN: 1091-5818 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012057894A1 (fr) 2010-10-26 2012-05-03 Quinnova Pharmaceuticals, Inc. Composition d'econazole et méthodes de traitement au moyen de cette composition
EP2672968A4 (fr) * 2010-10-26 2016-07-13 Quinnova Pharmaceuticals Inc Composition d'econazole et méthodes de traitement au moyen de cette composition
US20140073616A1 (en) * 2012-09-11 2014-03-13 Gary Marder Hydrocortisone nanotechnological delivery system
US9205093B2 (en) * 2012-09-11 2015-12-08 Gary Marder Hydrocortisone nanotechnological delivery system

Also Published As

Publication number Publication date
EP2231119A1 (fr) 2010-09-29
GB0724236D0 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
KR101790388B1 (ko) 부분불소화된 알칸에 기초된 국소 제약학적 조성물
AU2012260788B2 (en) Pharmaceutical composition for administration to nails
KR101619077B1 (ko) 비타민 ｄ 유사체 및 코르티코스테로이드를 포함하는 약제학적 분무 조성물
US20020107265A1 (en) Emulsion compositions for polyfunctional active ingredients
AU2010335654B2 (en) Cutaneous composition comprising vitamin D analogue and a mixture of solvent and surfactants
WO2020028694A1 (fr) Compositions liposomales et procédés d'utilisation
JPH0568444B2 (fr)
JP2002513749A5 (fr)
CN110352052A (zh) 阿普斯特的局部治疗组合物
JP5732471B2 (ja) 溶媒混合物およびビタミンｄ誘導体から成る医薬品組成物または類似体
CA2785249A1 (fr) Composition pharmaceutique comprenant un analogue de la vitamine d et un melange cosolvant-tensioactif
HU228742B1 (en) Topical compositions comprising ascomycins
JP2008502645A (ja) 油性相中にコルチコイドとビタミンｄ誘導体との組み合わせを含むスプレー形態の組成物
EP2231119A1 (fr) Mousses pharmaceutiques
CA2074503C (fr) Formulation pharmaceutique contenant du penciclovir
JPH0366618A (ja) 薬学的配合物
RU2538680C2 (ru) Фармацевтическая композиция для лечения атопического дерматита и способ ее получения
KR20220124175A (ko) 건선 및 기타 질병 치료를 위한 국소 시클로스포린
Khode et al. Lecithin Microemulsion Based Systems for Dermal Delivery of Drugs: A
AU2004264680A1 (en) Pharmaceutical compositions of lavendustin
HK1092699B (en) Pharmaceutical compositions of lavendustin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08860575

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008860575

Country of ref document: EP

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0820974

Country of ref document: BR

Free format text: PEDIDO RETIRADO, UMA VEZ QUE, SEGUNDO O ART. 216 INCISO 2O DA LPI, O DOCUMENTO DE PROCURACAO NAO FOI PROTOCOLADO EM SESSENTA DIAS CONTADOS DA PRATICA DO PRIMEIRO ATO DA PARTE NO PROCESSO, E NAO HOUVE MANIFESTACAO DO REQUERENTE FRENTE A PUBLICACAO DO ARQUIVAMENTO DA PETICAO (11.6.1) NA RPI 2317 DE 02/06/2015.